Literature DB >> 3831640

Parameter estimates for a QALY utility model.

J M Miyamoto, S A Eraker.   

Abstract

This paper discusses a utility model for quality adjusted life years (QALY). According to this model, the utility of Y years of survival in health state Q is bYrH(Q), where b is a scaling constant and r and H(Q) are parameters. The parameter r is shown to be interpretable as a representation of a patient's risk attitude with respect to survival duration. The parameter H(Q) represents the proportionate reduction in the utility of survival when health state Q prevails. Methods are described for estimating these parameters from the results of an individual patient utility assessment. Results are then reported for empirical estimation of parameters r and H(Q) from the preference judgments of a sample of 46 coronary artery disease patients. In this empirical study, health state Q takes on two values--survival with angina pectoris and survival free from angina pectoris. Estimated values of parameters r and H(Q) are discussed in relation to the decision analysis of coronary artery bypass graft surgery. Finally, it is argued that the model deserves consideration as a medical utility model, despite some preliminary evidence that assumptions of the model are descriptively false, because it provides a simple representation of the utility of survival duration and health quality. These aspects of health outcomes are known to be critically important in the expected utility analysis of health decisions.

Entities:  

Mesh:

Year:  1985        PMID: 3831640     DOI: 10.1177/0272989X8500500208

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  12 in total

Review 1.  Valuing health-related quality of life. Issues and controversies.

Authors:  P Dolan
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

2.  The burden of age-related macular degeneration: a value-based medicine analysis.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Joshua D Stein; Zachary Roth; Joseph Campanella; George R Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2005

3.  Cost-effectiveness analysis and policy choices: investing in health systems.

Authors:  C J Murray; J Kreuser; W Whang
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

4.  The standard gamble method: what is being measured and how it is interpreted.

Authors:  A Gafni
Journal:  Health Serv Res       Date:  1994-06       Impact factor: 3.402

5.  Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis.

Authors:  L A Lenert; R M Soetikno
Journal:  J Am Med Inform Assoc       Date:  1997 Jan-Feb       Impact factor: 4.497

Review 6.  The value of vision.

Authors:  Christine Knauer; Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

7.  Clinically important differences in Q-TWIST - one twist too many?

Authors:  Richard Stephens
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

8.  The Cost of Uncertain Life Span.

Authors:  Ryan D Edwards
Journal:  J Popul Econ       Date:  2008-06-01

9.  A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.

Authors:  J Wang; Z Zhao; B Barber; B Sherrill; M Peeters; J Wiezorek
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

10.  Is chloroquine better than artemisinin combination therapy as first line treatment in adult nigerians with uncomplicated malaria?-A cost effectiveness analysis.

Authors:  Shaibu O Bello; Aminu Chika; Aishatu Y Bello
Journal:  Afr J Infect Dis       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.